Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -2994.34 KRW | -203.02% |
| 2022 | 2906.49 KRW | 1729.93% |
| 2021 | -178.32 KRW | -142.47% |
| 2020 | 419.91 KRW | -56.79% |
| 2019 | 971.73 KRW | 121.65% |
| 2018 | 438.40 KRW | 12.07% |
| 2017 | 391.20 KRW | -12.87% |
| 2016 | 449.00 KRW | -96.95% |
| 2015 | 14.71 Thousand KRW | 2350.53% |
| 2014 | 600.40 KRW | -48.92% |
| 2013 | 1175.40 KRW | -77.74% |
| 2012 | 5281.00 KRW | 9.46% |
| 2011 | 4824.40 KRW | 551.77% |
| 2010 | 740.20 KRW | -12.19% |
| 2009 | 843.00 KRW | -69.99% |
| 2008 | 2809.20 KRW | 109.64% |
| 2007 | 1340.00 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -97.81 KRW | 98.32% |
| 2024 Q2 | -61.89 KRW | 36.72% |
| 2023 FY | - KRW | -203.02% |
| 2023 Q1 | 2115.93 KRW | 930.6% |
| 2023 Q4 | -5825.42 KRW | -985.96% |
| 2023 Q3 | 657.53 KRW | 480.36% |
| 2023 Q2 | -172.87 KRW | -108.17% |
| 2022 Q1 | 355.42 KRW | -83.83% |
| 2022 Q3 | 2214.33 KRW | -96.7% |
| 2022 Q4 | 205.31 KRW | -90.73% |
| 2022 Q2 | 67.05 Thousand KRW | 18767.26% |
| 2022 FY | - KRW | 1729.93% |
| 2021 Q4 | 2198.43 KRW | 2143.3% |
| 2021 FY | - KRW | -142.47% |
| 2021 Q1 | -736.20 KRW | -156.65% |
| 2021 Q2 | 20.00 KRW | 102.72% |
| 2021 Q3 | 98.00 KRW | 390.0% |
| 2020 Q1 | 72.00 KRW | -97.01% |
| 2020 Q3 | 84.40 KRW | 2244.44% |
| 2020 Q2 | 3.60 KRW | -95.0% |
| 2020 FY | - KRW | -56.79% |
| 2020 Q4 | 1299.64 KRW | 1439.86% |
| 2019 Q3 | -48.60 KRW | -109.5% |
| 2019 FY | - KRW | 121.65% |
| 2019 Q1 | 55.20 KRW | -85.22% |
| 2019 Q4 | 2409.85 KRW | 5058.54% |
| 2019 Q2 | 511.40 KRW | 826.45% |
| 2018 Q2 | 111.40 KRW | -71.52% |
| 2018 Q1 | 391.20 KRW | 1015.73% |
| 2018 FY | - KRW | 12.07% |
| 2018 Q3 | -16.60 KRW | -114.9% |
| 2018 Q4 | 373.51 KRW | 2350.06% |
| 2017 Q1 | 288.60 KRW | -62.07% |
| 2017 Q4 | -42.72 KRW | -165.52% |
| 2017 Q3 | 65.20 KRW | 41.74% |
| 2017 Q2 | 46.00 KRW | -84.06% |
| 2017 FY | - KRW | -12.87% |
| 2016 Q1 | 164.80 KRW | -99.77% |
| 2016 FY | - KRW | -96.95% |
| 2016 Q4 | 760.95 KRW | 23679.69% |
| 2016 Q3 | 3.20 KRW | -97.52% |
| 2016 Q2 | 128.80 KRW | -21.84% |
| 2015 FY | - KRW | 2350.53% |
| 2015 Q4 | 70.49 Thousand KRW | 151178.97% |
| 2015 Q3 | 46.60 KRW | -71.13% |
| 2015 Q2 | 161.40 KRW | -60.23% |
| 2015 Q1 | 405.80 KRW | -42.46% |
| 2014 FY | - KRW | -48.92% |
| 2014 Q1 | 209.00 KRW | 144.07% |
| 2014 Q4 | 705.22 KRW | 337.48% |
| 2014 Q3 | 161.20 KRW | 80.72% |
| 2014 Q2 | 89.20 KRW | -57.32% |
| 2013 Q3 | 52.20 KRW | -80.18% |
| 2013 Q4 | -474.20 KRW | -1008.43% |
| 2013 FY | - KRW | -77.74% |
| 2013 Q1 | 943.20 KRW | -87.69% |
| 2013 Q2 | 263.40 KRW | -72.07% |
| 2012 Q4 | 7664.81 KRW | 1728.44% |
| 2012 Q2 | 1182.00 KRW | -44.63% |
| 2012 FY | - KRW | 9.46% |
| 2012 Q3 | 419.20 KRW | -64.53% |
| 2012 Q1 | 2134.60 KRW | -86.97% |
| 2011 Q4 | 16.38 Thousand KRW | 2930.52% |
| 2011 Q1 | 789.60 KRW | 306.15% |
| 2011 Q2 | 133.80 KRW | -83.05% |
| 2011 FY | - KRW | 551.77% |
| 2011 Q3 | 540.60 KRW | 304.04% |
| 2010 FY | - KRW | -12.19% |
| 2010 Q4 | 194.41 KRW | 199.09% |
| 2010 Q3 | 65.00 KRW | -50.61% |
| 2010 Q2 | 131.60 KRW | -69.49% |
| 2010 Q1 | 431.40 KRW | -72.46% |
| 2009 Q2 | 331.60 KRW | 228.97% |
| 2009 Q3 | 96.20 KRW | -70.99% |
| 2009 Q1 | 100.80 KRW | -89.5% |
| 2009 Q4 | 1566.57 KRW | 1528.45% |
| 2009 FY | - KRW | -69.99% |
| 2008 Q4 | 959.83 KRW | 109.75% |
| 2008 Q3 | 457.60 KRW | -70.18% |
| 2008 Q2 | 1534.60 KRW | 209.64% |
| 2008 Q1 | 495.60 KRW | -62.11% |
| 2008 FY | - KRW | 109.64% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | 1308.00 KRW | 371.69% |
| 2007 Q3 | 277.30 KRW | -24.36% |
| 2007 Q2 | 366.60 KRW | -14.7% |
| 2007 Q1 | 429.76 KRW | 0.0% |